These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10930173)

  • 21. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four-drug salvage antiretroviral treatment including nelfinavir and efavirenz in highly treated children with congenital HIV disease.
    Manfredi R; Chiodo F
    Int J STD AIDS; 2000 Feb; 11(2):132-3. PubMed ID: 10678486
    [No Abstract]   [Full Text] [Related]  

  • 23. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Squires KE; Hammer SM; Fischl MA; Wu H; Cha R; Morse GD;
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1929-35. PubMed ID: 12760869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():37-8. PubMed ID: 11373775
    [No Abstract]   [Full Text] [Related]  

  • 25. I want a new drug. An overview of three new anti-HIV drugs.
    Simmons P
    Res Initiat Treat Action; 1998 Jun; 4(3):9-11. PubMed ID: 11365539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication.
    Ramratnam B; Ribeiro R; He T; Chung C; Simon V; Vanderhoeven J; Hurley A; Zhang L; Perelson AS; Ho DD; Markowitz M
    J Acquir Immune Defic Syndr; 2004 Jan; 35(1):33-7. PubMed ID: 14707789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
    Fisac C; Fumero E; Crespo M; Roson B; Ferrer E; Virgili N; Ribera E; Gatell JM; Podzamczer D
    AIDS; 2005 Jun; 19(9):917-25. PubMed ID: 15905672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What's new and what's next.
    Fakuda D
    Posit Dir News; 1998 Jan; 10(1):25-9. PubMed ID: 11365053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
    Gervasoni C; Vigano O; Grinelli E; Ortu M; Galli M; Rusconi S
    AIDS Patient Care STDS; 2007 Jan; 21(1):1-3. PubMed ID: 17263652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen.
    Chini M; Tsoupras AB; Mangafas N; Tsogas N; Papakonstantinou VD; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
    Int J Immunopathol Pharmacol; 2012; 25(1):247-58. PubMed ID: 22507337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.
    Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S
    Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Triple combinations regimens for HIV.
    Lancet Infect Dis; 2003 Nov; 3(11):682. PubMed ID: 14603888
    [No Abstract]   [Full Text] [Related]  

  • 34. [Long-term success in routine clinical practice. Effectiveness trial passed].
    MMW Fortschr Med; 2000; 142(3 Suppl):30-1. PubMed ID: 10893961
    [No Abstract]   [Full Text] [Related]  

  • 35. Probable interaction between efavirenz and cyclosporine.
    Tseng A; Nguyen ME; Cardella C; Humar A; Conly J
    AIDS; 2002 Feb; 16(3):505-6. PubMed ID: 11834972
    [No Abstract]   [Full Text] [Related]  

  • 36. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():12-3. PubMed ID: 15011576
    [No Abstract]   [Full Text] [Related]  

  • 38. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
    Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
    Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
    Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.